While the OlympiA trial demonstrated that the poly ADP ribose polymerase (PARP) inhibitor olaparib significantly improved DFS and OS in BRCA-mutated HER2-negative breast cancer, their role in BRCA-mutated HER2-positive breast cancer remains undefined [45]. Here, ERBB2 is linked to breast cancer.